EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review

Steve Halligan iD, Darren Boone iD, Lucinda Archer iD, Tariq Ahmad iD, Stuart Bloom iD, Manuel Rodriguez-Justo iD, Stuart A Taylor iD, Sue Mallett iD

Health Technology Assessment · 2021-07 · 25 (45) · 1-66

DOI: 10.3310/hta25450 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Health Technology Assessment, 2021-07. Verfasst von Steve Halligan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medical Imaging, University College London, London, UK. Hauptthemen laut MEDLINE: Crohn Disease. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Department of Health, Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Identification of biomarkers that predict severe Crohn’s disease is an urgent unmet research need, but existing research is piecemeal and haphazard.

Objective

To identify biomarkers that are potentially able to predict the development of subsequent severe Crohn’s disease.

Design

This was a prognostic systematic review with meta-analysis reserved for those potential predictors with sufficient existing research (defined as five or more primary studies). Data sources PubMed and EMBASE searched from inception to 1 January 2016, updated to 1 January 2018. Review methods Eligible studies were studies that compared biomarkers in patients who did or did not subsequently develop severe Crohn’s disease. We excluded biomarkers that had insufficient research evidence. A clinician and two statisticians independently extracted data relating to predictors, severe disease definitions, event numbers and outcomes, including odds/hazard ratios. We assessed risk of bias. We searched for associations with subsequent severe disease rather than precise estimates of strength. A random-effects meta-analysis was performed separately for odds ratios.

Results

In total, 29,950 abstracts yielded just 71 individual studies, reporting 56 non-overlapping cohorts. Five clinical biomarkers (Montreal behaviour, age, disease duration, disease location and smoking), two serological biomarkers (anti- Saccharomyces cerevisiae antibodies and anti-flagellin antibodies) and one genetic biomarker (nucleotide-binding oligomerisation domain-containing protein 2) displayed statistically significant prognostic potential. Overall, the strongest association with subsequent severe disease was identified for Montreal B2 and B3 categories (odds ratio 4.09 and 6.25, respectively).

Limitations

Definitions of severe disease varied widely, and some studies confounded diagnosis and prognosis. Risk of bias was rated as ‘high’ in 92% of studies overall. Some biomarkers that are used regularly in daily practice, for example C-reactive protein, were studied too infrequently for meta-analysis.

Conclusions

Research for individual biomarkers to predict severe Crohn’s disease is scant, heterogeneous and at a high risk of bias. Despite a large amount of potential research, we encountered relatively few biomarkers with data sufficient for meta-analysis, identifying only eight biomarkers with potential predictive capability. Future work We will use existing data sets to develop and then validate a predictive model based on the potential predictors identified by this systematic review. Contingent on the outcome of that research, a prospective external validation may prove clinically desirable. Study registration This study is registered as PROSPERO CRD42016029363. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 25, No. 45. See the NIHR Journals Library website for further project information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseBiomarkersHumansImmunologic TestsPrognosisProspective Studies

Stichwörter der Autor:innen

BIOLOGICAL MARKERSBIOMARKERSCROHN’S DISEASEDIAGNOSTIC ACCURACYMETA-ANALYSISPREDICTIONPROGNOSISREVIEW, SYSTEMATIC

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Centre for Medical Imaging, University College London, London, UK.
  • Centre for Prognosis Research, School of Primary, Community and Social Care, Keele University, Keele, UK.
  • Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
  • Department of Gastroenterology, University College Hospital, London, UK.
  • Department of Histopathology, University College Hospital, London, UK.

ORCID-Profile: Steve Halligan, Darren Boone, Lucinda Archer, Tariq Ahmad, Stuart Bloom, Manuel Rodriguez-Justo, Stuart A Taylor, Sue Mallett

Förderung

  • Department of Health
  • Health Technology Assessment programme

Zitieren

APA

Halligan, S., Boone, D., Archer, L., Ahmad, T., Bloom, S., Rodriguez-Justo, M., Taylor, S. A., & Mallett, S. (2021). Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review. Health Technology Assessment, 25(45), 1-66. https://doi.org/10.3310/hta25450

Vancouver

Halligan S, Boone D, Archer L, Ahmad T, Bloom S, Rodriguez-Justo M, et al. Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review. Health Technology Assessment. 2021;25(45):1-66. doi:10.3310/hta25450

BibTeX
@article{Halligan2021,
  author = {Halligan, Steve and Boone, Darren and Archer, Lucinda and Ahmad, Tariq and Bloom, Stuart and Rodriguez-Justo, Manuel and Taylor, Stuart A and Mallett, Sue},
  title = {Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review},
  journal = {Health Technology Assessment},
  year = {2021},
  volume = {25},
  number = {45},
  pages = {1--66},
  doi = {10.3310/hta25450}
}
Kostenlos starten →